logo
U.S. vaccine panel rejects flu shots with a specific preservative, despite safety data

U.S. vaccine panel rejects flu shots with a specific preservative, despite safety data

CBC27-06-2025
The Trump administration's new vaccine advisers on Thursday endorsed this fall's flu vaccinations for just about every American — but only if they use certain shots free of a preservative that has been safely used in vaccines for decades.
What is normally a routine step in preparing for the upcoming flu season drew intense scrutiny after U.S. Health Secretary Robert F. Kennedy Jr. abruptly fired the influential 17-member Advisory Committee on Immunization Practices (ACIP)and handpicked replacements that include several vaccine skeptics.
The seven-member panel bucked another norm Thursday as it discussed the safety of a preservative used in less than five per cent of U.S. flu vaccinations: It deliberated based only on a presentation from an anti-vaccine group's former leader — without allowing the usual public airing of scientific data from the U.S. Centers for Disease Control and Prevention.
The preservative, thimerosal, has been used for decades in certain vaccines that come in multi-dose vials, to prevent contamination as each dose is withdrawn. Its controversy stems from containing a small amount of a particular type of mercury. However, the CDC's own data shows it is safe, and on Friday the World Health Organization stated in a press briefing that there was no evidence of risk.
"Thimerosal has been reviewed multiple times by multiple agencies, including WHO, and it's clear from the evidence that there is no evidence of harm from the use of thimerosal," Dr. Katherine O'Brien from WHO told reporters in reaction to the U.S. panel decision.
Thimerosal contains a minute amount of ethyl mercury, which breaks down quickly in the body and is swiftly removed, unlike methyl mercury, the type of mercury found in the environment which can build up in the body and cause harm. In Canada, a handful of multi-dose influenza vaccines approved for use by Health Canada contain thimerosal, but the vast majority of routine childhood vaccines do not.
Single-dose flu shots unaffected
Study after study has found no evidence that thimerosal causes autism, a myth long pushed by anti-vaccine groups, or poses any safety risks. Yet since 2001, all vaccines routinely used for U.S. children age 6 years or younger have already come in thimerosal-free formulas.
The advisory panel voted to back the usual U.S. recommendation that nearly everyone age six months and older get an annual flu vaccination, but then voted 5-1 with one abstention that these had to be thimerosal-free formulations.
This would include single-dose shots that already are the most common type of flu vaccination, and would rule out the subset of flu vaccine dispensed in multi-dose vials.
"There is still no demonstrable evidence of harm," one panelist, Dr. Joseph Hibbeln, a psychiatrist formerly with the National Institutes of Health, said in acknowledging the committee wasn't following its usual practice of acting on evidence.
But he argued that "we have to respect the fear of mercury" that he said might dissuade some people from getting vaccinated.
Panel blocked CDC's analysis
Lyn Redwood, formerly of the Kennedy-founded anti-vaccine group Children's Health Defense, gave the presentation on thimerosal in front of the panel, arguing that it was a neurotoxin.
The version of Redwood's presentation posted to the CDC's website earlier this week initially included a reference to a study that does not exist. The report she gave to the committee was significantly shorter, removing a reference to that study and another slide saying she did not have any conflicts of interest.
"With the vote on thimerosal this afternoon, the new committee has turned the ACIP process into a farce," said former CDC vaccine adviser Dr. Fiona Havers, who resigned last week over Kennedy's changes to vaccine policy.
Medical groups decried the panel's lack of transparency in blocking a CDC analysis of thimerosal that concluded there was no link between the preservative and neurodevelopmental disorders, including autism. The data had been posted on the committee's website Tuesday, but was later removed — because, according to ACIP member Dr. Robert Malone, the report hadn't been authorized by Kennedy's office. Panel members said they had read it.
The ACIP helps the CDC determine who should be vaccinated against a long list of diseases, and when, and its recommendations have a big impact on availability and insurance coverage of vaccines in the U.S.
Normally the CDC's director would decide whether to accept ACIP's recommendation, but the Senate has not yet confirmed nominee Susan Monarez. Administration officials said Kennedy would make that decision.
While Thursday's debate involved only a small fraction of flu vaccines, some public health experts contend the discussion unnecessarily raised doubt about vaccine safety. Already, fewer than half of Americans get their yearly flu vaccinations, and mistrust in vaccines overall is growing.
"Selective use of data and omission of established science undermines public trust and fuels misinformation," said Dr. Sean O'Leary of the American Academy of Pediatrics (AAP). He said of the new panelists, "Nothing about their recent actions have been science-based or transparent."
WATCH: Misinformation one of the factors behind decline in childhood vaccination globally:
Decline in childhood vaccination fuelled by global conflicts, misinformation: Lancet
3 days ago
Duration 2:01
A new study published in the Lancet medical journal suggests childhood vaccinations have stagnated or declined since 2010. The authors say geopolitical instability is fuelling the drop in some countries, but misinformation is largely driving the decline in high-income countries.
The pediatrics group announced Wednesday that it would no longer be participating in the ACIP meetings, with president Sue Kressly saying in a video statement that "with the committee dismissals, it is no longer a credible process." The AAP will continue publishing its own vaccination recommendations.
The flu votes marked the final step of a two-day meeting that alarmed pediatricians and other doctors' groups, who pointed to new panelists' lack of expertise in how to properly track vaccine safety — and a shift in focus which appears to boost anti-vaccine messaging.
Of special concern was the announcement by panel chairman Martin Kulldorff to reevaluate the "cumulative effect" of the children's vaccine schedule — the list of immunizations given at different times throughout childhood. That reflects the scientifically debunked notion that children today get too many vaccinations for their immune systems.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jordan Peterson taking time off to fight new health setback, according to his daughter
Jordan Peterson taking time off to fight new health setback, according to his daughter

National Post

time44 minutes ago

  • National Post

Jordan Peterson taking time off to fight new health setback, according to his daughter

Canadian psychologist, best-selling author and media commentator Jordan Peterson is taking time off for medical reasons, according to his daughter. Article content 'JBP is taking some time off of everything,' wrote podcast host and CEO of Peterson Academy, Mikhaila Peterson, on her X account earlier this week. Article content Article content Hey guys, @jordanbpeterson is taking some time off of everything. He was diagnosed with CIRS (chronic inflammatory response syndrome) due to a genetic predisposition that causes the immune system to have an inability to identify and detoxify mold/bacteria in indoor air (the… — Mikhaila Peterson (@MikhailaFuller) August 13, 2025 Article content Article content She says her father, a sometimes columnist for National Post, has been diagnosed with a condition known as chronic inflammatory response syndrome, or CIRS, and that it results in an immune deficiency that inhibits identifying and detoxifying indoor mold and bacteria. Article content Article content 'Recently he was exposed to a particularly moldy environment while helping clean out my grandfather's house after he passed away which severely flared symptoms. … He's really been suffering from this badly since 2017 we just didn't know what it was called,' she wrote. Article content This is the latest health setback for Peterson, 62, who fought to beat a benzodiazepine addiction in 2019. Article content After Peterson's addiction struggles were revealed, he announced he had developed akathisia — a condition which can cause restlessness, mental distress and an inability to sit still. Article content However, his daughter said that isn't an aspect of the present setback. She wrote on X: 'To be crystal clear — this isn't about akathisia or medication. He's not on any medication. It's an immune system dysfunction.' Article content Article content Conservative Leader, Pierre Poilievre has wished Peterson well. In a post to X on Saturday, he wrote: 'Praying for a swift recovery,' adding, 'The world needs his prodigious mind and solid principles now more than ever.' Article content Praying for a swift recovery for my friend Dr. @jordanbpeterson. The world needs his prodigious mind and solid principles now more than ever. — Pierre Poilievre (@PierrePoilievre) August 15, 2025

2 Top Dividend Stocks to Buy on the Dip
2 Top Dividend Stocks to Buy on the Dip

Globe and Mail

time5 hours ago

  • Globe and Mail

2 Top Dividend Stocks to Buy on the Dip

Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025

Hundreds may have been exposed to rabies at bat-infested cabins in Grand Teton National Park
Hundreds may have been exposed to rabies at bat-infested cabins in Grand Teton National Park

CTV News

timea day ago

  • CTV News

Hundreds may have been exposed to rabies at bat-infested cabins in Grand Teton National Park

Health officials are working to alert hundreds of people in dozens of states and several countries who may have been exposed to rabies in bat-infested cabins in Wyoming's Grand Teton National Park over the past few months. As of Friday, none of the bats found in some of the eight linked cabins at Jackson Lake Lodge had tested positive for rabies. But the handful of dead bats found and sent to the Wyoming State Veterinary Laboratory in Laramie for testing were probably only a small sample of the likely dozens that colonized the attic above the row of cabins, Wyoming State Health Officer Dr. Alexia Harrist said. Other bats weren't killed but got shooed out through cabin doors and windows. Meanwhile, the vast majority never flapped down from the attic into living spaces. Health officials thus deemed it better safe than sorry to alert everybody who has stayed in the cabins recently that they might have been exposed by being bitten or scratched. Especially when people are sleeping, a bat bite or scratch can go unseen and unnoticed. 'What we're really concerned about is people who saw bats in their rooms and people who might have had direct contact with a bat,' Harrist said Friday. The cabins have been unoccupied, with no plans to reopen, since concessionaire Grand Teton Lodge Company discovered the bat problem July 27. Bats are a frequent vector of the rabies virus. Once symptoms occur — muscle aches, vomiting, itching, to name a few — rabies is almost always fatal in humans. The good news is a five-shot prophylactic regimen over a two-week period soon after exposure is highly effective in preventing illness, Harrist noted. The cabins opened for the summer season in May after being vacant over the winter. Based on the roughly 250 reservations through late July, health officials estimated that up to 500 people had stayed in the cabins. They were trying to reach people in 38 states and seven countries through those states' health agencies and, in the case of foreign visitors, the U.S. Centers for Disease Control and Prevention. Others who have not been alerted yet but stayed in cabins 516, 518, 520, 522, 524, 526, 528 and 530 this year should tell health officials or a doctor immediately, Harrist said. Health officials were recommending prophylactic shots for people who fit certain criteria, such as deep sleepers who found a bat in their room, and children too young to say that they had seen a bat. The Wyoming Department of Health had no ongoing concern about visitor safety at the Jackson Lake Lodge area. That includes a Federal Reserve economic policy symposium Aug. 21-23 that takes place at Jackson Lake Lodge every summer. 'The lodge company has done a fantastic job of doing their due diligence of making sure everyone that is coming in for that, and for all other visits this year, are going to be as safe as possible,' said Emily Curren, Wyoming's public health veterinarian. 'Three or four' dead bats from the cabins tested negative and one that was mangled did not have enough brain tissue to be testable, Curren said. All were brown bats, which come in two species: 'little' and 'big,' with the larger ones more than twice as big. Officials were unsure which species these were, but both are common in Wyoming. They typically live in colonies of 30 to 100 individuals, Curren said. 'That's a lot of bats that we cannot rule out a risk of rabies being in,' Curren said. 'There's no way for us to know for certain about every single bat that got into these rooms.' There are no plans to exterminate the bats, Grand Teton National Park spokesperson Emily Davis said. Devices fitted to the building were keeping the bats from getting back in after flying out in pursuit of insects to eat, they said. Sejal Govindarao And Mead Gruver (), The Associated Press

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store